Related Experiment Video
Updated: May 7, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Immunohistochemical expression of RBP2 and LSD1 in papillary thyroid carcinoma
Lingling Kong1, Guoan Zhang, Xu Wang
1Department of Pathology, Basic Science School, Jining Medical University, Jining, Shandong, China; Kong001199@yahoo.com, cuiwenmd@163.com.
Purpose:
To investigate the prognostic significance of LSD1 and RBP2 expression in patients with papillary thyroid carcinoma.
Materials And Methods:
LSD1 and RBP2 expressions were detected by immunohistochemistry in surgically resected samples from thyroid adenoma, papillary thyroid carcinoma and paracancerous tissues.
Results:
To be members of histone demethylases, LSD1 and RBP2 were both localized mainly to the thyroid cell nucleus. Despite the fact that both RBP2 and LSD1 expressions were higher in papillary thyroid carcinoma than in paracancerous tissues (U=-3.855, p=0.000; U=-5.575, p=0.000) and thyroid adenoma (U=-1.972, p=0.049; U=-3.190, p=0.001), they did not show us statistical correlation (r=-0.149, p=0.270). Like LSD1 (U=-2.286, p=0.022), RBP2 expression was less frequently in paracancerous tissues than in thyroid adenoma (U=-1.985, p=0.047). Neither LSD1 nor RBP2 expression was significantly associated with age, gender, stage status, tumor size, and lymph node metastases (p>0.05).
Conclusions:
Both LSD1 and RBP2 are well related with the occurrence and malignant transformation of papillary thyroid carcinoma. Though the positive expression of both LSD1 and RBP2 can be used to estimate the potentiality of thyroid carcinoma and help for the adjuvant treatment, LSD1 is a more sensitive molecular marker than RBP2 on thyroid cancer diagnosis.
